334826-98-1

334826-98-1 structure

Name: Gisadenafil
Chemical Name: 5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4H-pyrazolo[4,3-d]pyrimidin-7-one
CAS Number: 334826-98-1
Molecular Formula: C₂₃H₃₃N₇O₅S
Molecular Weight: 519.61700
Catalog: Pharmaceutical intermediate Heterocyclic compound Pyridine compound Ethylpyridine
Create Date: 2018-12-26 20:18:33
Modify Date: 2024-01-03 01:23:23
Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)[1].

Name	5-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylpyridin-3-yl]-3-ethyl-2-(2-methoxyethyl)-4H-pyrazolo[4,3-d]pyrimidin-7-one
Synonyms	unii-s6g4r7di1c gisadenafil

Description	Gisadenafil (UK-369003) is a specific, orally active phosphodiesterase 5 (PDE5) inhibitor with an IC50 of 3.6 nM and prevents degradation of cyclic guanosine monophosphate (cGMP)[1].
Target	PDE5A:3.6 nM (IC50) PDE1A:9.1 μM (IC50)
In Vitro	Since some PDE5 inhibitors can also interact with PDE1 isotypes found within the cerebral vasculature, the specificity of Gisadenafil for PDE5 is confirmed. This is directly tested with recombinant PDE5A and PDE1A overexpressed in COS-7 cells. The IC50 of Gisadenafil for PDE5A is 3.6 nM. In contrast, the IC50 of Gisadenafil for PDE1A is 9.1 μM, an approximately 2500-fold difference in specificity[1].
In Vivo	Gisadenafil (2 mg/kg; intraperitoneal injection; for 2 hours; male Tat-transgenic mice) treatment largely restores the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Gisadenafil also restores the dilation of small (<25 μm) arterioles following hypercapnia, although it fails to restore full dilation of larger (>25 μm) vessels[1]. Animal Model: Male Tat-transgenic (Tat-tg) mice (8 weeks old) exposed to hypercapnia[1] Dosage: 2 mg/kg Administration: Intraperitoneal injection; for 2 hours Result: Largely restored the normal increase in cortical flow following hypercapnia in Tat-tg mice (17.5% above baseline). Also restored the dilation of small (<25 μm) arterioles following hypercapnia.
References	[1]. Silva J, et al. Transient hypercapnia reveals an underlying cerebrovascular pathology in a murine model for HIV-1 associated neuroinflammation: role of NO-cGMP signaling and normalization by inhibition of cyclic nucleotide phosphodiesterase-5. J Neuroinflammation. 2012 Nov 20;9:253. [2]. Rawson DJ, et al. The discovery of UK-369003, a novel PDE5 inhibitor with the potential for oral bioavailability and dose-proportional pharmacokinetics. Bioorg Med Chem. 2012 Jan 1;20(1):498-509.

Density	1.41
Boiling Point	701.3±70.0 °C(Predicted)
Molecular Formula	C₂₃H₃₃N₇O₅S
Molecular Weight	519.61700
Exact Mass	519.22600
PSA	143.92000
LogP	2.07190
Storage condition	2-8°C

Precursor 9
334828-19-2 504-29-0 334828-10-3 247582-73-6
247582-63-4 247582-68-9 334828-03-4 1228361-26-9
16250-08-1
DownStream 1
334827-98-4